Fosamax® is manufactured by Merck and prescribed to increase bone density in patients menopausal women with osteoporosis. Fosamax® side effects include: osteonecrosis; dead jaw; esophageal cancer; vision alterations; esophageal erosions; esophageal ulcers; esophageal stricture or perforation; oropharyngeal ulceration; and femur fractures.
Osteonecrosis of the jaw (ONJ) is a disease in which bone tissue in the jaw does not heal after minor trauma such as tooth extraction or oral surgery. Fosamax® dead jaw causes pain and soreness with an exposed bone; pain or swelling in the infected jaw; infection; drainage; numbness. The highest risk factors when taking bisphosphonates is ONJ, especially intravenously. Other high risk lifestyles not recommended while taking Fosamax® and may cause more serious complications are the use of steroids; previous history of cancer; previous history of osteoporosis or Paget’s disease; and traumatic dental procedure, such as tooth extraction or dental implants.